Genvec (FRA:GVC2) Long-Term Debt : €0.00 Mil (As of Mar. 2017)

View and export this data going back to . Start your Free Trial

What is Genvec Long-Term Debt?

Genvec's Long-Term Debt for the quarter that ended in Mar. 2017 was €0.00 Mil.

Genvec Long-Term Debt Historical Data

The historical data trend for Genvec's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genvec Long-Term Debt Chart

Genvec Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Long-Term Debt

Get a 7-Day Free Trial

Genvec Quarterly Data
	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17
Long-Term Debt	Get a 7-Day Free Trial															-	-	-	-	-

Genvec (FRA:GVC2) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Genvec Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Genvec's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Genvec (FRA:GVC2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genvec Inc (FRA:GVC2) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.genvec.com

Genvec Inc was incorporated under the laws of the state of Delaware on December 7, 1992.The Company is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. Its development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus or RSV, herpes simplex virus or HSV, and malaria. In the area of animal health the Company is developing vaccines against foot-and-mouth disease or FMD. In collaboration with Novartis, the Companys hearing and balance disorders program is focused on the restoration of hearing and balance function through the regeneration of critical cells of the inner ear. The Company is currently developing preventative vaccines, against RSV and malaria and therapeutic vaccine against HSV.

Genvec (FRA:GVC2) Headlines

No Headlines